Cysteine

While Cysteine is primarily used in pediatric populations, its use in adults requiring Total Parenteral Nutrition (TPN) is occasionally indicated when methionine-to-cysteine conversion is impaired (e.g., severe liver disease).

• Standard TPN Additive: In adults, the dosage is typically calculated based on the total protein (amino acid) requirement. A common range is 7 mg to 22 mg of Cysteine per gram of amino acids administered.
• Maximum Dose: Dosing is generally limited by the solubility and stability of the final TPN admixture, often not exceeding 1000 mg per day unless specifically directed by a metabolic specialist.

Cysteine dosing in pediatrics is highly specific and based on weight and developmental stage. According to the American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines:

• Preterm and Term Infants (< 1 month): The recommended dose is typically 22 mg of L-cysteine hydrochloride per gram of amino acids. For example, if an infant is receiving 3 g/kg/day of amino acids, the cysteine dose would be 66 mg/kg/day.
• Pediatric Patients (1 month to 12 years): The dose may be adjusted based on the specific amino acid product being used, often ranging from 7 mg to 22 mg per gram of amino acids.
• Adolescents: Dosing begins to mirror adult requirements as metabolic pathways mature.

Renal Impairment

Cysteine and its nitrogenous metabolites are excreted by the kidneys. In patients with impaired renal function, there is an increased risk of nitrogen accumulation (azotemia). Healthcare providers should monitor Blood Urea Nitrogen (BUN) closely and may need to reduce the overall amino acid load, including Cysteine.

Hepatic Impairment

Since the liver is the primary site of amino acid metabolism, patients with hepatic insufficiency or liver failure may develop hyperammonemia (high ammonia levels). Dosage should be adjusted based on the patient's ability to tolerate nitrogen, and liver function tests (LFTs) must be monitored frequently.

Elderly Patients

Clinical studies for L-cysteine injection generally do not include sufficient numbers of patients aged 65 and over. Dosing should be cautious, starting at the lower end of the range, reflecting the higher frequency of decreased hepatic, renal, or cardiac function.

Cysteine hydrochloride injection is a concentrate and must never be administered by direct intravenous injection. It is strictly for addition to amino acid solutions used in TPN.

• Preparation: A pharmacist must add Cysteine to the amino acid bag under sterile conditions (ISO Class 5 environment).
• Administration: The final TPN solution is administered via a central or peripheral venous catheter, depending on the osmolarity of the final mixture.
• Storage: The concentrated vial should be stored at room temperature (20°C to 25°C). Once added to the TPN bag, the solution should be used immediately or stored under refrigeration for no more than 24 hours.

In the context of TPN, Cysteine is administered continuously or in cycles. If a TPN bag is delayed or missed, healthcare providers will typically restart the infusion at the prescribed rate. Do not "double up" the concentration in the next bag to compensate for a missed dose, as this can lead to metabolic imbalances or precipitation of the IV solution.

An overdose of Cysteine in TPN can lead to amino acid toxicity and metabolic derangements.

• Signs of Overdose: Metabolic acidosis (excess acid in the blood), hyperammonemia (confusion, lethargy), and azotemia (elevated BUN).
• Emergency Measures: If an overdose is suspected, the infusion should be stopped immediately. The patient's acid-base balance and electrolyte levels must be evaluated. Treatment is supportive, focusing on correcting fluid and electrolyte imbalances and managing ammonia levels.

> Important: Follow your healthcare provider's dosing instructions precisely. The stability of Cysteine in TPN is highly sensitive to pH and temperature; do not adjust your dose or administration method without medical guidance.

Because Cysteine is an amino acid naturally found in the body, "side effects" are often related to the metabolic consequences of administration via TPN rather than the molecule itself. In neonatal populations, common observations include:

• Metabolic Acidosis: Cysteine hydrochloride is an acidifying agent. It can lower the pH of the blood, which may cause rapid breathing or lethargy in infants.
• Electrolyte Imbalances: Changes in potassium, magnesium, or phosphate levels as the body utilizes the amino acids for growth (anabolism).
• Injection Site Reactions: Redness, swelling, or phlebitis (inflammation of the vein) at the site of the IV catheter.

• Hyperammonemia: An elevation of ammonia levels in the blood, which can occur if the liver is overwhelmed by the nitrogen load. This may present as irritability or poor feeding in infants.
• Azotemia: An increase in Blood Urea Nitrogen (BUN), indicating the kidneys are processing a high load of nitrogenous waste.
• Nausea and Vomiting: More common in older pediatric patients or adults receiving rapid amino acid infusions.

• Hepatoxicity: Long-term TPN use containing amino acids can lead to TPN-associated cholestasis (bile flow blockage) or liver scarring.
• Aluminum Toxicity: Many Cysteine injections contain trace amounts of aluminum. In patients with impaired kidney function or premature infants, aluminum can accumulate to toxic levels in the bone and central nervous system.
• Hypersensitivity: Rare allergic reactions including rash or urticaria (hives).

> Warning: Stop taking Cysteine and call your doctor immediately if you experience any of these serious symptoms:

1. 1Severe Metabolic Acidosis: Symptoms include rapid, shallow breathing, extreme fatigue, or confusion. This requires immediate adjustment of the IV solution's acetate/chloride ratio.
2. 2Aluminum Toxicity Symptoms: In infants, this may manifest as impaired neurological development or "brittle bones" (osteomalacia). This is a cumulative risk from long-term TPN.
3. 3Hyperammonemia Crisis: Symptoms include seizures, vomiting, or significant changes in mental status. High ammonia is toxic to the brain.
4. 4Pulmonary Edema: Fluid in the lungs, characterized by difficulty breathing or a "crackling" sound when breathing, often due to fluid overload from the TPN carrier solution.
5. 5Anaphylaxis: Though extremely rare, signs include swelling of the face/throat, difficulty swallowing, or severe wheezing.

Patients on long-term Cysteine-supplemented TPN are at risk for:

• Bone Mineral Density Loss: Chronic exposure to the acid load of Cysteine and trace aluminum can lead to metabolic bone disease.
• Liver Dysfunction: Prolonged parenteral nutrition can lead to Parenteral Nutrition-Associated Liver Disease (PNALD), characterized by elevated bilirubin and liver enzymes.
• Vitamin/Mineral Deficiencies: If the TPN is not perfectly balanced, the rapid growth spurred by amino acid intake can deplete stores of copper, selenium, or zinc.

There are currently no FDA black box warnings specifically for Cysteine hydrochloride injection. However, the FDA requires a prominent warning regarding Aluminum Toxicity in the "Warnings and Precautions" section of the label. This warning highlights that the product contains aluminum that may be toxic, particularly to premature neonates with impaired renal function. Exposure to more than 4 to 5 mcg/kg/day of parenteral aluminum is associated with central nervous system and bone toxicity.

Report any unusual symptoms or changes in your child's behavior to your healthcare provider immediately. Regular blood monitoring is the best way to prevent and detect these side effects early.

Cysteine must only be used by healthcare professionals trained in the management of parenteral nutrition. It is a highly concentrated solution that requires careful dilution. The most critical safety concern is the maintenance of the correct acid-base balance and the prevention of mineral precipitation in the IV bag, which can be fatal if infused.

No FDA black box warnings for Cysteine. However, as noted in the side effects section, the Aluminum Toxicity Warning is the most significant clinical precaution mandated by the FDA for this drug class.

• Allergic Reactions / Anaphylaxis Risk: While Cysteine is an endogenous amino acid, the hydrochloride salt or the manufacturing process may trigger sensitivities. Monitor for rash, itching, or respiratory distress during the initiation of the infusion.
• Metabolic Acidosis: Cysteine HCl adds a significant chloride load to the TPN. In infants with limited renal compensatory mechanisms, this can lead to hyperchloremic metabolic acidosis. Healthcare providers must balance this by using acetate salts of other amino acids.
• Hepatotoxicity: Monitor liver function closely. Amino acid infusions can exacerbate pre-existing liver disease or lead to new-onset cholestasis, especially in low-birth-weight infants.
• Nephrotoxicity and Azotemia: In patients with renal impairment, the nitrogen load from Cysteine can cause a rapid rise in BUN. Use with extreme caution in patients with anuria (failure of the kidneys to produce urine).
• Pulmonary Vascular Precipitates: If Cysteine is mixed improperly with calcium and phosphorus, solid precipitates can form. These can lodge in the lungs (pulmonary embolism), causing severe respiratory distress or death.

Patients receiving Cysteine in TPN require frequent laboratory monitoring, often daily in the initial stages:

• Serum Electrolytes: Sodium, potassium, chloride, and bicarbonate.
• Renal Function: Serum creatinine and Blood Urea Nitrogen (BUN).
• Liver Function: ALT, AST, alkaline phosphatase, and total bilirubin.
• Acid-Base Status: Arterial or venous blood gas (pH, pCO2).
• Blood Glucose: To monitor for glucose intolerance often associated with TPN.
• Ammonia Levels: Especially if the patient shows signs of lethargy or irritability.

Cysteine is typically used in hospitalized neonates or pediatric patients who do not drive. For adults receiving home TPN, Cysteine itself does not cause sedation; however, the underlying condition requiring TPN may affect the ability to drive safely.

There is no direct interaction between Cysteine and alcohol. However, alcohol consumption is generally contraindicated in patients with the severe liver or gastrointestinal diseases that necessitate parenteral nutrition.

Cysteine is discontinued when the patient transitions to enteral (oral or tube) feeding. There is no "withdrawal syndrome," but the transition must be managed carefully to ensure the patient maintains adequate protein and caloric intake. Tapering the TPN rate is standard practice to prevent rebound hypoglycemia, though this is related to the dextrose content, not the Cysteine.

> Important: Discuss all your medical conditions, especially kidney or liver problems, with your healthcare provider before starting Cysteine-supplemented nutrition.

Cysteine hydrochloride injection is relatively inert regarding direct drug-drug interactions, but it is highly reactive in terms of chemical compatibility.

• Highly Alkaline Solutions: Cysteine should never be mixed with highly alkaline drugs or solutions (e.g., certain barbiturates or sodium bicarbonate) in the same IV line. The high pH will cause the Cysteine to oxidize into cystine, which is insoluble and will precipitate, potentially causing an embolism.

• Calcium and Phosphate: This is the most critical interaction in TPN pharmacy. Cysteine is often added to TPN because its acidity increases the solubility of calcium and phosphate, allowing higher concentrations to be delivered for bone health. However, if the concentrations exceed specific solubility curves, calcium phosphate crystals will form.
• Loop Diuretics (e.g., Furosemide): These can increase the renal excretion of electrolytes and may worsen the electrolyte imbalances caused by the nitrogen load of Cysteine.

• Tetracycline Antibiotics: Some studies suggest that amino acid infusions may slightly decrease the effectiveness of tetracyclines, though this is rarely clinically significant in a TPN setting.
• Levodopa: High-protein diets or amino acid infusions can compete with levodopa for transport across the blood-brain barrier, potentially reducing the efficacy of the medication in patients with Parkinson's disease.

• Enteral Protein: If a patient is receiving both TPN and oral food, the total protein intake must be monitored to avoid hyperammonemia.
• Vitamin C: While the EPC list mentions Vitamin C, it is important to note that Vitamin C (ascorbic acid) is often added to TPN. It acts as an antioxidant and may help stabilize the redox state of Cysteine, though this is a beneficial interaction managed by the pharmacist.

• Sulfur Supplements (MSM, SAMe): Taking additional sulfur-containing supplements alongside Cysteine-supplemented TPN may increase the risk of sulfur-related metabolic byproduct accumulation.
• St. John's Wort: While no direct interaction exists, St. John's Wort can affect liver enzymes, which may complicate the monitoring of TPN-associated liver issues.

• Urinary Ketones: High levels of Cysteine or its metabolites may occasionally cause false-positive results in certain urine ketone tests that use the nitroprusside reaction.
• Serum Amino Acid Chromatography: Exogenous Cysteine will obviously elevate measured plasma cysteine levels, which must be accounted for when screening for inborn errors of metabolism.

Interaction Management Strategy

• Mechanism: Most interactions are physical (precipitation) or metabolic (competition for transporters).
• Clinical Consequence: Precipitation can be fatal; metabolic competition can reduce drug efficacy.
• Management: Use a 0.22-micron in-line filter for all TPN infusions to catch any precipitates. Always flush IV lines between incompatible medications.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even if they seem unrelated to your nutritional therapy.

Cysteine must NEVER be used in the following circumstances:

1. 1Hypersensitivity: Known allergy to L-cysteine or any component of the formulation (e.g., the hydrochloride salt).
2. 2Inborn Errors of Amino Acid Metabolism: Conditions such as Cystinosis or certain types of homocystinuria where the body cannot properly process sulfur-containing amino acids. Administering extra Cysteine in these cases can lead to toxic accumulation in organs like the kidneys and eyes.
3. 3Severe Acidosis: Because Cysteine hydrochloride is an acidifying agent, its use in patients who are already in a state of severe, uncompensated metabolic acidosis is contraindicated until the underlying pH balance is addressed.
4. 4Anuria: Patients with complete kidney failure who are not on dialysis cannot clear the nitrogenous waste products of Cysteine metabolism, leading to rapid, dangerous levels of azotemia.

Conditions requiring a careful risk-benefit analysis include:

• Severe Hepatic Encephalopathy: The nitrogen load may worsen brain swelling and confusion due to elevated ammonia.
• Pulmonary Edema or Heart Failure: The fluid volume required to deliver TPN must be carefully balanced against the risk of fluid overload.
• Renal Insufficiency: Requires lower doses and frequent monitoring of BUN and creatinine.

There is little evidence of cross-sensitivity between L-cysteine and other drugs. However, patients who have had severe reactions to N-acetylcysteine (NAC) should be monitored closely, as the molecules are chemically related. Additionally, patients with sensitivities to sulfites (often used as preservatives in other medications) generally do not have a sensitivity to Cysteine, as Cysteine is a natural amino acid, not a sulfite preservative.

> Important: Your healthcare provider will evaluate your complete medical history, including any genetic metabolic screenings, before prescribing Cysteine.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of L-cysteine hydrochloride injection in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether Cysteine can cause fetal harm when administered to a pregnant woman. However, Cysteine is a normal component of the human diet and is essential for fetal growth. In clinical practice, Cysteine is used in pregnant women requiring TPN only if the potential benefit justifies the potential risk to the fetus. Monitoring for maternal hyperammonemia is essential to prevent fetal distress.

L-cysteine is a natural component of breast milk. When administered intravenously as part of TPN, it is unlikely to achieve concentrations in breast milk that would be harmful to a nursing infant, provided the mother's plasma levels are within the physiological range. However, caution should be exercised, and the infant should be monitored for any signs of protein intolerance if the mother is receiving high-dose parenteral nutrition.

This is the primary population for Cysteine hydrochloride injection. It is specifically approved for neonates (including preterm) and pediatric patients.

• Growth Effects: Cysteine is vital for weight gain and nitrogen balance in infants.
• Special Considerations: The risk of aluminum toxicity is highest in this group due to immature kidney function. Healthcare providers must calculate the total aluminum exposure from all TPN components.

Elderly patients are more likely to have decreased renal and hepatic function. While Cysteine is not commonly used as a standalone supplement in the elderly, when used in TPN, the dose must be individualized. There is an increased risk of azotemia and fluid overload in this population. Frequent monitoring of BUN and cardiac status is recommended.

In patients with renal impairment (GFR < 60 mL/min/1.73m²), Cysteine metabolites can accumulate. Dosage reductions of the total amino acid solution are often necessary. For patients on dialysis, Cysteine is cleared during the procedure, and supplemental doses may be required on dialysis days, though this is managed by the renal nutrition team.

Patients with liver disease (Child-Pugh Class B or C) are at high risk for hyperammonemia when receiving amino acid infusions. Cysteine should be used cautiously, and the patient should be monitored for signs of encephalopathy (confusion, tremors). If ammonia levels rise significantly, the amino acid infusion rate must be reduced.

> Important: Special populations, especially premature infants, require individualized medical assessment and precise nutritional calculations by a multidisciplinary team.

Cysteine is a sulfur-containing amino acid. Its primary molecular mechanism involves its role as a precursor for Glutathione (L-gamma-glutamyl-L-cysteinyl-glycine). Cysteine provides the rate-limiting sulfhydryl (-SH) group for glutathione synthesis via the enzymes glutamate-cysteine ligase and glutathione synthetase.

Additionally, Cysteine is essential for the synthesis of Taurine, which is critical for bile acid conjugation and brain development in infants. It also acts as a structural component in proteins, where its thiol groups oxidize to form disulfide bridges, stabilizing the tertiary and quaternary structures of enzymes and hormones.

The pharmacodynamic effect of Cysteine is primarily nutritional and metabolic. The "onset of action" in the context of TPN is the improvement of nitrogen balance and steady weight gain, which is typically observed over several days of therapy. There is no "tolerance" development to Cysteine, as it is a fundamental nutrient. However, the body's ability to handle the acid load (chloride) and nitrogen load determines the maximum tolerable dose.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | 10-15% (to albumin) |

| Half-life | Approximately 1.5 - 2 hours (plasma) |

| Tmax | Immediate (IV infusion) |

| Metabolism | Hepatic (Conversion to sulfate, taurine, glutathione) |

| Excretion | Renal (>90% as metabolites) |

• Molecular Formula: C3H7NO2S (L-cysteine)
• Molecular Weight: 121.16 g/mol
• Solubility: Highly soluble in water; solubility decreases as pH increases (converts to cystine).
• Structure: A three-carbon chain with an amino group, a carboxyl group, and a terminal thiol group. In clinical products, it is usually provided as the hydrochloride salt (C3H7NO2S · HCl) to improve stability and solubility.

Cysteine is classified as an Amino Acid [EPC]. Within the therapeutic area of parenteral nutrition, it is considered a "semi-essential" or "conditionally essential" amino acid. It is related to other sulfur-containing amino acids like Methionine, though it does not require the same metabolic conversion steps that Methionine does, making it safer for neonatal use.